Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics Reports First Quarter 2017 Financial Results and Provides Update on Operational Progress
- Pre-enrollment activities underway for SER-109 ECOSPOR III clinical study initiation; Company expects study start in mid-year - - Continued pipeline progress with both SER-287 and SER-262 Phase 1b studies; Data read-outs expected in the second half of 2017 - - Conference call at 8 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2017-- Seres Therapeutics Inc. (NASDAQ:MCRB) today reported first quarter 2017 fin... 
Seres Therapeutics Announces Participation at Two Upcoming Investor Conferences
CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 1, 2017-- Seres Therapeutics Inc. (NASDAQ:MCRB) today announced that management will participate in two upcoming investor conferences: Bank of America Merrill Lynch Healthcare Conference on Tuesday, May 16, 2017 in Las Vegas, NV; presentation at 3 p.m. PDT. UBS Global Healthcare Conference on Monday, May 22, 2017 in New York, NY; presentation at 1:30 p.m. EDT. ... 
Seres Therapeutics to Host First Quarter 2017 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2017
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Apr. 28, 2017-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on Thursday, May 4, 2017 at 8:00 a.m. EDT to discuss first quarter 2017 results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 11167224. To ... 
There are currently no upcoming events scheduled.
Stock Quote
 + 0.14 (1.43%)
05/24/17 11:10 a.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.